TD Asset Management Inc Has $2.62 Million Stake in Haemonetics Co. (NYSE:HAE)

TD Asset Management Inc reduced its position in shares of Haemonetics Co. (NYSE:HAE) by 39.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,646 shares of the medical instruments supplier’s stock after selling 20,800 shares during the period. TD Asset Management Inc owned approximately 0.06% of Haemonetics worth $2,618,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Capital Research Global Investors raised its holdings in Haemonetics by 2.3% in the 1st quarter. Capital Research Global Investors now owns 6,674,751 shares of the medical instruments supplier’s stock valued at $569,690,000 after acquiring an additional 151,183 shares in the last quarter. Vanguard Group Inc. lifted its position in Haemonetics by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 5,406,309 shares of the medical instruments supplier’s stock worth $462,293,000 after purchasing an additional 25,451 shares during the period. Wellington Management Group LLP grew its stake in Haemonetics by 3.2% during the fourth quarter. Wellington Management Group LLP now owns 3,268,083 shares of the medical instruments supplier’s stock worth $279,454,000 after buying an additional 101,029 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Haemonetics by 7.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 826,731 shares of the medical instruments supplier’s stock worth $70,697,000 after buying an additional 59,670 shares in the last quarter. Finally, Westfield Capital Management Co. LP raised its position in shares of Haemonetics by 27.2% in the 4th quarter. Westfield Capital Management Co. LP now owns 712,061 shares of the medical instruments supplier’s stock valued at $60,888,000 after buying an additional 152,098 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Stock Up 1.1 %

Haemonetics stock opened at $73.26 on Friday. The company has a quick ratio of 2.33, a current ratio of 3.76 and a debt-to-equity ratio of 1.35. The company has a market capitalization of $3.73 billion, a PE ratio of 31.99, a PEG ratio of 1.33 and a beta of 0.30. The firm’s fifty day moving average is $81.55 and its 200 day moving average is $83.87. Haemonetics Co. has a 12-month low of $70.74 and a 12-month high of $97.97.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $1.02 EPS for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.01). The firm had revenue of $336.17 million during the quarter, compared to analyst estimates of $335.08 million. Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. The company’s revenue was up 8.0% on a year-over-year basis. During the same period last year, the business posted $1.05 EPS. As a group, sell-side analysts predict that Haemonetics Co. will post 4.58 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on HAE shares. BTIG Research initiated coverage on Haemonetics in a research note on Tuesday. They issued a “buy” rating and a $112.00 price target on the stock. Barrington Research lifted their target price on Haemonetics from $107.00 to $108.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Needham & Company LLC raised Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 target price for the company in a research note on Wednesday, June 12th. Bank of America started coverage on shares of Haemonetics in a research note on Wednesday. They issued a “neutral” rating and a $85.00 price target on the stock. Finally, Citigroup lowered their price objective on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a research report on Thursday, August 22nd. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Haemonetics presently has an average rating of “Moderate Buy” and an average price target of $104.50.

Insider Buying and Selling at Haemonetics

In other news, insider Stewart W. Strong sold 4,312 shares of the stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $91.15, for a total value of $393,038.80. Following the completion of the sale, the insider now directly owns 18,196 shares of the company’s stock, valued at $1,658,565.40. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, EVP Anila Lingamneni sold 2,136 shares of the company’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $90.00, for a total value of $192,240.00. Following the completion of the transaction, the executive vice president now directly owns 21,410 shares of the company’s stock, valued at $1,926,900. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Stewart W. Strong sold 4,312 shares of Haemonetics stock in a transaction on Friday, July 26th. The stock was sold at an average price of $91.15, for a total value of $393,038.80. Following the sale, the insider now owns 18,196 shares in the company, valued at $1,658,565.40. The disclosure for this sale can be found here. Company insiders own 1.80% of the company’s stock.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.